JP2004502642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502642A5 JP2004502642A5 JP2001558420A JP2001558420A JP2004502642A5 JP 2004502642 A5 JP2004502642 A5 JP 2004502642A5 JP 2001558420 A JP2001558420 A JP 2001558420A JP 2001558420 A JP2001558420 A JP 2001558420A JP 2004502642 A5 JP2004502642 A5 JP 2004502642A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- methyl
- morpholinyl
- alkyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 description 62
- 239000001257 hydrogen Substances 0.000 description 62
- 125000000217 alkyl group Chemical group 0.000 description 60
- 150000001875 compounds Chemical class 0.000 description 53
- 150000002431 hydrogen Chemical class 0.000 description 51
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 46
- 125000003118 aryl group Chemical group 0.000 description 35
- 125000000753 cycloalkyl group Chemical group 0.000 description 32
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 29
- -1 alkylamide Chemical group 0.000 description 28
- 125000003545 alkoxy group Chemical group 0.000 description 27
- 229910052757 nitrogen Inorganic materials 0.000 description 26
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 25
- 125000000547 substituted alkyl group Chemical group 0.000 description 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 21
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 17
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 125000005017 substituted alkenyl group Chemical group 0.000 description 15
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 13
- 125000004103 aminoalkyl group Chemical group 0.000 description 12
- 125000004093 cyano group Chemical group *C#N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 125000004426 substituted alkynyl group Chemical group 0.000 description 11
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical class C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 208000023504 respiratory system disease Diseases 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000003520 cannabinoid receptor affecting agent Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 0 CC(*)(C1N2*)[C@]1c([n](**)c1c3C=CC(*)(*)C=C1*)c3C2=O Chemical compound CC(*)(C1N2*)[C@]1c([n](**)c1c3C=CC(*)(*)C=C1*)c3C2=O 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 150000001602 bicycloalkyls Chemical group 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 230000008518 non respiratory effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- CTKINSOISVBQLD-GSVOUGTGSA-N (R)-Glycidol Chemical compound OC[C@@H]1CO1 CTKINSOISVBQLD-GSVOUGTGSA-N 0.000 description 1
- RKZCDADRRFKROG-KMGMCLHJSA-N 1-(2-cyclohexylethyl)-7-methoxy-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CCC1CCCCC1 RKZCDADRRFKROG-KMGMCLHJSA-N 0.000 description 1
- NGBQGZULVBXWKI-MNIAQESNSA-N 1-(2-ethoxyethyl)-7-methoxy-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C12=CC=CC(OC)=C2N(CCOCC)C(C)=C1C(=O)N[C@H]1[C@@](C2)(C)CCC2C1(C)C NGBQGZULVBXWKI-MNIAQESNSA-N 0.000 description 1
- UMSJZSKEUCVDDU-UCPOHXDKSA-N 1-(2-morpholin-4-ylethyl)-5-nitro-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrazole-3-carboxamide Chemical compound N([C@@H]1C(C)(C)C2CC[C@]1(C2)C)C(=O)C(=N1)C=C([N+]([O-])=O)N1CCN1CCOCC1 UMSJZSKEUCVDDU-UCPOHXDKSA-N 0.000 description 1
- ZSBNYNLNQAALQY-XHYACHTCSA-N 1-(2-morpholin-4-ylethyl)-5-pentoxy-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrazole-3-carboxamide Chemical compound CCCCCOC1=CC(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=NN1CCN1CCOCC1 ZSBNYNLNQAALQY-XHYACHTCSA-N 0.000 description 1
- GOTMKWHLCZVWNF-MNIAQESNSA-N 1-[2-(dimethylamino)ethyl]-7-methoxy-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound COC1=CC=CC2=C1N(CCN(C)C)C(C)=C2C(=O)N[C@H]1[C@@](C2)(C)CCC2C1(C)C GOTMKWHLCZVWNF-MNIAQESNSA-N 0.000 description 1
- SAPSVILUXSCISL-KMGMCLHJSA-N 1-[2-[di(propan-2-yl)amino]ethyl]-7-methoxy-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound COC1=CC=CC2=C1N(CCN(C(C)C)C(C)C)C(C)=C2C(=O)N[C@@H]1C(C)(C)C2CC[C@@]1(C)C2 SAPSVILUXSCISL-KMGMCLHJSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- YECUDGCOHUBKEM-QGZVFWFLSA-N 2,5-dimethyl-1-(2-morpholin-4-ylethyl)-n-[(2r)-1-phenylpropan-2-yl]pyrrole-3-carboxamide Chemical compound C([C@@H](C)NC(=O)C1=C(N(CCN2CCOCC2)C(C)=C1)C)C1=CC=CC=C1 YECUDGCOHUBKEM-QGZVFWFLSA-N 0.000 description 1
- VARGLVSWMATKND-UCPOHXDKSA-N 2-(2-morpholin-4-ylethyl)-5-nitro-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrazole-3-carboxamide Chemical compound N([C@@H]1C(C)(C)C2CC[C@]1(C2)C)C(=O)C1=CC([N+]([O-])=O)=NN1CCN1CCOCC1 VARGLVSWMATKND-UCPOHXDKSA-N 0.000 description 1
- NAFSGIMUDROETJ-UHFFFAOYSA-N 2-[(2,6-dimethylphenyl)methyl]-6-methoxy-5-(2-morpholin-4-ylethyl)pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N(CC=3C(=CC=CC=3C)C)C=CC=22)=C1N2CCN1CCOCC1 NAFSGIMUDROETJ-UHFFFAOYSA-N 0.000 description 1
- UKWKFSKFWUTFRX-UHFFFAOYSA-N 2-[(2-fluorophenyl)methyl]-6-methoxy-5-(2-morpholin-4-ylethyl)pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N(CC=3C(=CC=CC=3)F)C=CC=22)=C1N2CCN1CCOCC1 UKWKFSKFWUTFRX-UHFFFAOYSA-N 0.000 description 1
- UAAIPGIFCADKPE-UHFFFAOYSA-N 2-cyclopentyl-6-methoxy-5-(2-morpholin-4-ylethyl)pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N(C3CCCC3)C=CC=22)=C1N2CCN1CCOCC1 UAAIPGIFCADKPE-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- JIXREYOBFPHPQG-UWJIBMLQSA-N 2-methyl-1-(2-morpholin-4-ylethyl)-4,5-diphenyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrrole-3-carboxamide Chemical compound C1COCCN1CCN1C(C)=C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JIXREYOBFPHPQG-UWJIBMLQSA-N 0.000 description 1
- JWPGFZBOKXSSAE-LFXFHBMYSA-N 2-methyl-1-(2-morpholin-4-ylethyl)-5-phenyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrrole-3-carboxamide Chemical compound C1COCCN1CCN1C(C)=C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)C=C1C1=CC=CC=C1 JWPGFZBOKXSSAE-LFXFHBMYSA-N 0.000 description 1
- STTXUMSIHQWORP-UHFFFAOYSA-N 2-methyl-1-(2-morpholin-4-ylethyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC2C(C3CCC2(C)C3)(C)C)C=CN1CCN1CCOCC1 STTXUMSIHQWORP-UHFFFAOYSA-N 0.000 description 1
- AMFCVKOCHWUBAG-NRFANRHFSA-N 2-methyl-n-[(1s)-1-(3-methyl-1,2,4-oxadiazol-5-yl)-2-phenylethyl]-1-(2-morpholin-4-ylethyl)pyrrole-3-carboxamide Chemical compound CC1=NOC([C@H](CC=2C=CC=CC=2)NC(=O)C2=C(N(CCN3CCOCC3)C=C2)C)=N1 AMFCVKOCHWUBAG-NRFANRHFSA-N 0.000 description 1
- WVKPYYLOFMTDHB-UHFFFAOYSA-N 2-norbornyl radical Chemical group C1CC2[CH]CC1C2 WVKPYYLOFMTDHB-UHFFFAOYSA-N 0.000 description 1
- OLWWQYROAWRRMR-UHFFFAOYSA-N 3,4-dihydro-2h-quinolin-1-yl-[5-fluoro-7-methoxy-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone Chemical compound C1=2C(OC)=CC(F)=CC=2C(C(=O)N2C3=CC=CC=C3CCC2)=C(C)N1CCN1CCOCC1 OLWWQYROAWRRMR-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- BMYHCXBZNSSQFT-OGGJSMKJSA-N 5,7-dimethoxy-2-methyl-1-(2-morpholin-4-ylethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound CC1=C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)C2=CC(OC)=CC(OC)=C2N1CCN1CCOCC1 BMYHCXBZNSSQFT-OGGJSMKJSA-N 0.000 description 1
- MXJVPIIMPVGSCK-DLOYZTDZSA-N 5-benzyl-6-methoxy-2-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N([C@H]3[C@@]4(C)CCC(C4)C3(C)C)C=CC=22)=C1N2CC1=CC=CC=C1 MXJVPIIMPVGSCK-DLOYZTDZSA-N 0.000 description 1
- BPCWSLRVZAOONI-XMWUBULVSA-N 5-butyl-6-methoxy-2-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrido[4,3-b]indol-1-one Chemical compound C12=CC=CC(OC)=C2N(CCCC)C2=C1C(=O)N([C@H]1[C@@]3(C)CCC(C3)C1(C)C)C=C2 BPCWSLRVZAOONI-XMWUBULVSA-N 0.000 description 1
- FINTYTPBRFYBCW-QPBYVCLMSA-N 5-fluoro-7-methoxy-2-methyl-1-(2-morpholin-4-ylethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC(F)=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CCN1CCOCC1 FINTYTPBRFYBCW-QPBYVCLMSA-N 0.000 description 1
- YJBCXXBDTPUCPP-OGGJSMKJSA-N 5-fluoro-7-methoxy-2-methyl-1-(3-morpholin-4-ylpropyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC(F)=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CCCN1CCOCC1 YJBCXXBDTPUCPP-OGGJSMKJSA-N 0.000 description 1
- LIJWNPZQIZRZFJ-UHFFFAOYSA-N 5-fluoro-7-methoxy-n-(2-methoxyphenyl)-2-methyl-1-(2-morpholin-4-ylethyl)indole-3-carboxamide Chemical compound COC1=CC=CC=C1NC(=O)C(C1=CC(F)=CC(OC)=C11)=C(C)N1CCN1CCOCC1 LIJWNPZQIZRZFJ-UHFFFAOYSA-N 0.000 description 1
- XXZCLKCFTHJCQG-LIRQYPNKSA-N 5-methoxy-1-(2-morpholin-4-ylethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrazole-3-carboxamide Chemical compound COC1=CC(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=NN1CCN1CCOCC1 XXZCLKCFTHJCQG-LIRQYPNKSA-N 0.000 description 1
- DHWXPOMVUUYBGK-UHFFFAOYSA-N 6-methoxy-2-(2-methoxyethyl)-5-(2-morpholin-4-ylethyl)pyrido[4,3-b]indol-1-one Chemical compound C12=C(OC)C=CC=C2C=2C(=O)N(CCOC)C=CC=2N1CCN1CCOCC1 DHWXPOMVUUYBGK-UHFFFAOYSA-N 0.000 description 1
- XIOBJOPZJWKCIV-UHFFFAOYSA-N 6-methoxy-2-(2-methoxyphenyl)-5-(2-morpholin-4-ylethyl)pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC=C1N1C(=O)C(C2=CC=CC(OC)=C2N2CCN3CCOCC3)=C2C=C1 XIOBJOPZJWKCIV-UHFFFAOYSA-N 0.000 description 1
- JTHVKCNGXTTXIF-HXUWFJFHSA-N 6-methoxy-5-(2-morpholin-4-ylethyl)-2-[(2r)-1-phenylpropan-2-yl]pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N([C@H](C)CC=3C=CC=CC=3)C=CC=22)=C1N2CCN1CCOCC1 JTHVKCNGXTTXIF-HXUWFJFHSA-N 0.000 description 1
- QYOXVDHZVYJTMY-IMIJRDQBSA-N 6-methoxy-5-(2-morpholin-4-ylethyl)-2-[(3r,4r)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N([C@H]3C(C4CC[C@]3(C)C4)(C)C)C=CC=22)=C1N2CCN1CCOCC1 QYOXVDHZVYJTMY-IMIJRDQBSA-N 0.000 description 1
- QYOXVDHZVYJTMY-OGGJSMKJSA-N 6-methoxy-5-(2-morpholin-4-ylethyl)-2-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N([C@@H]3C(C4CC[C@@]3(C)C4)(C)C)C=CC=22)=C1N2CCN1CCOCC1 QYOXVDHZVYJTMY-OGGJSMKJSA-N 0.000 description 1
- UFNLQUUMXCSEQA-UHFFFAOYSA-N 6-methoxy-5-(2-morpholin-4-ylethyl)-2-propylpyrido[4,3-b]indol-1-one Chemical compound C12=C(OC)C=CC=C2C=2C(=O)N(CCC)C=CC=2N1CCN1CCOCC1 UFNLQUUMXCSEQA-UHFFFAOYSA-N 0.000 description 1
- RGLUCTFRNHDAOB-KVVHPSQQSA-N 7-methoxy-1-(2-methoxyethyl)-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C12=CC=CC(OC)=C2N(CCOC)C(C)=C1C(=O)N[C@H]1[C@@](C2)(C)CCC2C1(C)C RGLUCTFRNHDAOB-KVVHPSQQSA-N 0.000 description 1
- CPTXZVAIZCMESQ-UHFFFAOYSA-N 7-methoxy-1-(2-morpholin-4-ylethyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC2C(C3CCC2(C)C3)(C)C)=NN1CCN1CCOCC1 CPTXZVAIZCMESQ-UHFFFAOYSA-N 0.000 description 1
- VQGDMQICNRCQEH-UHFFFAOYSA-N 7-methoxy-1-(2-morpholin-4-ylethyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC2C(C3CCC2(C)C3)(C)C)=CN1CCN1CCOCC1 VQGDMQICNRCQEH-UHFFFAOYSA-N 0.000 description 1
- JSRQMGXAMVWHLE-UHFFFAOYSA-N 7-methoxy-1-(2-morpholin-4-ylethyl)-n-(2,2,6,6-tetramethylcyclohexyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC2C(CCCC2(C)C)(C)C)=NN1CCN1CCOCC1 JSRQMGXAMVWHLE-UHFFFAOYSA-N 0.000 description 1
- QRPFZKVPDUOZAU-UHFFFAOYSA-N 7-methoxy-1-(2-morpholin-4-ylethyl)-n-naphthalen-1-ylindazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC=2C3=CC=CC=C3C=CC=2)=NN1CCN1CCOCC1 QRPFZKVPDUOZAU-UHFFFAOYSA-N 0.000 description 1
- IEPNKLPPFVSJSN-DLOYZTDZSA-N 7-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1C2=C(OC)C=CC=C2C(C(=O)N[C@H]2[C@@]3(C)CCC(C3)C2(C)C)=C1C IEPNKLPPFVSJSN-DLOYZTDZSA-N 0.000 description 1
- XWGGGOMMJKYRJR-UHFFFAOYSA-N 7-methoxy-2-methyl-1-(2-morpholin-4-ylethyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC2C(C3CCC2(C)C3)(C)C)=C(C)N1CCN1CCOCC1 XWGGGOMMJKYRJR-UHFFFAOYSA-N 0.000 description 1
- SWXSXJGOHIPCQP-DLOYZTDZSA-N 7-methoxy-2-methyl-1-(2-phenoxyethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@H]2[C@@]3(C)CCC(C3)C2(C)C)=C(C)N1CCOC1=CC=CC=C1 SWXSXJGOHIPCQP-DLOYZTDZSA-N 0.000 description 1
- SQTXGPFIQPMERT-DXIPVMJCSA-N 7-methoxy-2-methyl-1-(2-piperidin-4-ylethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CCC1CCNCC1 SQTXGPFIQPMERT-DXIPVMJCSA-N 0.000 description 1
- JNOBXWYKDSWKHL-ZGOHAYIYSA-N 7-methoxy-2-methyl-1-(2-pyrrolidin-1-ylethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@H]2[C@@]3(C)CCC(C3)C2(C)C)=C(C)N1CCN1CCCC1 JNOBXWYKDSWKHL-ZGOHAYIYSA-N 0.000 description 1
- XWRHWCKKYSXXDL-ZGOHAYIYSA-N 7-methoxy-2-methyl-1-(pyridin-3-ylmethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CC1=CC=CN=C1 XWRHWCKKYSXXDL-ZGOHAYIYSA-N 0.000 description 1
- SULYTHAJECIDRM-NTEAZJJZSA-N 7-methoxy-2-methyl-1-[2-(1-methylpyrrolidin-2-yl)ethyl]-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@H]2[C@@]3(C)CCC(C3)C2(C)C)=C(C)N1CCC1CCCN1C SULYTHAJECIDRM-NTEAZJJZSA-N 0.000 description 1
- DJHGDVDDQPYURF-KMGMCLHJSA-N 7-methoxy-2-methyl-1-[3-(4-methylpiperazin-1-yl)propyl]-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CCCN1CCN(C)CC1 DJHGDVDDQPYURF-KMGMCLHJSA-N 0.000 description 1
- RPGZRVZCBGRDRB-QQBUZJHSSA-N 7-methoxy-2-methyl-1-pentyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C12=CC=CC(OC)=C2N(CCCCC)C(C)=C1C(=O)N[C@H]1[C@@](C2)(C)CCC2C1(C)C RPGZRVZCBGRDRB-QQBUZJHSSA-N 0.000 description 1
- GFWZOUZKTAJZMA-QYWJTTNJSA-N 7-methoxy-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]-1h-indole-3-carboxamide Chemical compound COC1=CC=CC2=C1NC(C)=C2C(=O)N[C@@H]1C(C)(C)C2CC[C@@]1(C)C2 GFWZOUZKTAJZMA-QYWJTTNJSA-N 0.000 description 1
- XZPAOPCTRNKGEW-UHFFFAOYSA-N 7-methoxy-n-(2-methoxy-5-methylphenyl)-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound COC1=CC=C(C)C=C1NC(=O)C(C1=CC=CC(OC)=C11)=NN1CCN1CCOCC1 XZPAOPCTRNKGEW-UHFFFAOYSA-N 0.000 description 1
- OLUHPADYRYQIDW-UHFFFAOYSA-N 7-methoxy-n-(2-methoxyphenyl)-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound COC1=CC=CC=C1NC(=O)C(C1=CC=CC(OC)=C11)=NN1CCN1CCOCC1 OLUHPADYRYQIDW-UHFFFAOYSA-N 0.000 description 1
- ALYXSSFEDASHDJ-FQEVSTJZSA-N 7-methoxy-n-[(1s)-1-(2-methyltetrazol-5-yl)-2-phenylethyl]-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H](CC=2C=CC=CC=2)C2=NN(C)N=N2)=NN1CCN1CCOCC1 ALYXSSFEDASHDJ-FQEVSTJZSA-N 0.000 description 1
- OMRMTIYZBXTTOP-UHFFFAOYSA-N 7-methoxy-n-[(2-methoxyphenyl)methyl]-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound COC1=CC=CC=C1CNC(=O)C(C1=CC=CC(OC)=C11)=NN1CCN1CCOCC1 OMRMTIYZBXTTOP-UHFFFAOYSA-N 0.000 description 1
- YLPNKBNBWHXBFF-UHFFFAOYSA-N 7-methoxy-n-methyl-n-(3-methylphenyl)-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N(C)C=2C=C(C)C=CC=2)=NN1CCN1CCOCC1 YLPNKBNBWHXBFF-UHFFFAOYSA-N 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- XCVSUBXPCXFEKN-SFHVURJKSA-N [(2s)-2-(methoxymethyl)pyrrolidin-1-yl]-[1-(2-morpholin-4-ylethyl)-5-pentoxypyrazol-3-yl]methanone Chemical compound CCCCCOC1=CC(C(=O)N2[C@@H](CCC2)COC)=NN1CCN1CCOCC1 XCVSUBXPCXFEKN-SFHVURJKSA-N 0.000 description 1
- VFZWVZXGXPNSIY-LOACHALJSA-N [(2s)-2-(methoxymethyl)pyrrolidin-1-yl]-[7-(morpholin-4-ylmethyl)-6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound COC[C@@H]1CCCN1C(=O)C1=NN2C(CN3CCOCC3)CCOC2=C1 VFZWVZXGXPNSIY-LOACHALJSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- IGWVDMIHDOVSLO-UHFFFAOYSA-N n-(2-ethylphenyl)-5-fluoro-7-methoxy-2-methyl-1-(2-morpholin-4-ylethyl)indole-3-carboxamide Chemical compound CCC1=CC=CC=C1NC(=O)C(C1=CC(F)=CC(OC)=C11)=C(C)N1CCN1CCOCC1 IGWVDMIHDOVSLO-UHFFFAOYSA-N 0.000 description 1
- CIAWPBGHCLCHDG-UHFFFAOYSA-N n-(4-fluorophenyl)-7-methoxy-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC=2C=CC(F)=CC=2)=NN1CCN1CCOCC1 CIAWPBGHCLCHDG-UHFFFAOYSA-N 0.000 description 1
- OKWBNHVZFDQPFV-UHFFFAOYSA-N n-(5-chloro-2-methoxyphenyl)-7-methoxy-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound COC1=CC=C(Cl)C=C1NC(=O)C(C1=CC=CC(OC)=C11)=NN1CCN1CCOCC1 OKWBNHVZFDQPFV-UHFFFAOYSA-N 0.000 description 1
- VRLOEKGMYGEXSQ-CQSZACIVSA-N n-[(2r)-butan-2-yl]-5-fluoro-7-methoxy-2-methyl-1-(2-morpholin-4-ylethyl)indole-3-carboxamide Chemical compound C12=C(OC)C=C(F)C=C2C(C(=O)N[C@H](C)CC)=C(C)N1CCN1CCOCC1 VRLOEKGMYGEXSQ-CQSZACIVSA-N 0.000 description 1
- GHCVCXTUXXGJRL-IBGZPJMESA-N n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]-7-methoxy-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H](CC=2C=CC=CC=2)C(N)=O)=NN1CCN1CCOCC1 GHCVCXTUXXGJRL-IBGZPJMESA-N 0.000 description 1
- FRGGVSWJEBUPRL-NRFANRHFSA-N n-[(2s)-1-hydroxy-3-phenylpropan-2-yl]-2-methyl-1-(2-morpholin-4-ylethyl)indole-3-carboxamide Chemical compound C([C@@H](CO)NC(=O)C1=C(N(C2=CC=CC=C21)CCN1CCOCC1)C)C1=CC=CC=C1 FRGGVSWJEBUPRL-NRFANRHFSA-N 0.000 description 1
- RIZAADJUTMSLDP-OAQYLSRUSA-N n-[(3r)-1-benzylpyrrolidin-3-yl]-7-methoxy-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@H]2CN(CC=3C=CC=CC=3)CC2)=NN1CCN1CCOCC1 RIZAADJUTMSLDP-OAQYLSRUSA-N 0.000 description 1
- RIZAADJUTMSLDP-NRFANRHFSA-N n-[(3s)-1-benzylpyrrolidin-3-yl]-7-methoxy-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H]2CN(CC=3C=CC=CC=3)CC2)=NN1CCN1CCOCC1 RIZAADJUTMSLDP-NRFANRHFSA-N 0.000 description 1
- 125000004971 nitroalkyl group Chemical group 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZUGVYAVSPOHDQS-UHFFFAOYSA-N pyrido[4,3-b]indol-1-one Chemical compound C1=CC=CC2=C3C(=O)N=CC=C3N=C21 ZUGVYAVSPOHDQS-UHFFFAOYSA-N 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18181800P | 2000-02-11 | 2000-02-11 | |
| PCT/US2001/004131 WO2001058869A2 (en) | 2000-02-11 | 2001-02-08 | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004502642A JP2004502642A (ja) | 2004-01-29 |
| JP2004502642A5 true JP2004502642A5 (https=) | 2008-03-13 |
Family
ID=22665935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001558420A Pending JP2004502642A (ja) | 2000-02-11 | 2001-02-08 | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6653304B2 (https=) |
| EP (1) | EP1254115A2 (https=) |
| JP (1) | JP2004502642A (https=) |
| AR (1) | AR027406A1 (https=) |
| AU (1) | AU2001234958A1 (https=) |
| CA (1) | CA2399791A1 (https=) |
| PE (1) | PE20020746A1 (https=) |
| WO (1) | WO2001058869A2 (https=) |
Families Citing this family (230)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2340445A1 (en) | 1998-05-04 | 1999-11-11 | The University Of Connecticut | Novel analgesic and immunomodulatory cannabinoids |
| US7897598B2 (en) * | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
| US7589220B2 (en) * | 1998-06-09 | 2009-09-15 | University Of Connecticut | Inhibitors of the anandamide transporter |
| US7276613B1 (en) | 1998-11-24 | 2007-10-02 | University Of Connecticut | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| US7161016B1 (en) | 1998-11-24 | 2007-01-09 | University Of Connecticut | Cannabimimetic lipid amides as useful medications |
| CA2387764A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Peripheral cannabinoid receptor (cb2) selective ligands |
| US7741365B2 (en) * | 1999-10-18 | 2010-06-22 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
| US6900236B1 (en) * | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
| US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US6943266B1 (en) * | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| EP1361876A4 (en) | 2001-01-26 | 2004-03-31 | Univ Connecticut | NEW CANNABIMIMETIC LIGANDS |
| DE60237431D1 (de) | 2001-01-29 | 2010-10-07 | Univ Connecticut | Rezeptor-selektive cannabimimetische aminoalkylindole |
| JP4312594B2 (ja) | 2001-07-13 | 2009-08-12 | ユニバーシティ オブ コネチカット | 新規な二環式及び三環式カンナビノイド |
| AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| CA2457922A1 (en) * | 2001-08-31 | 2003-03-13 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
| US7666867B2 (en) * | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
| EP1461027A4 (en) * | 2001-12-07 | 2005-09-07 | Univ Virginia Commonwealth | TREATMENT OF NEOPLASIA |
| WO2003075917A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| EP1483283A4 (en) | 2002-03-13 | 2007-04-11 | Signum Biosciences Inc | MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE |
| FR2838438A1 (fr) * | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
| DE60320784D1 (de) * | 2002-06-06 | 2008-06-19 | Yissum Res Dev Co | Stände zur modulierung des knochenwachstums |
| TW200402417A (en) * | 2002-06-21 | 2004-02-16 | Akzo Nobel Nv | 1-[(Indol-3-yl)carbonyl]piperazine derivatives |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| JP4202319B2 (ja) | 2002-07-29 | 2008-12-24 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ベンゾジオキソール |
| AU2003265663A1 (en) | 2002-08-23 | 2004-03-11 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
| HRP20050053A2 (en) | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| MXPA05003317A (es) * | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
| US20040077650A1 (en) * | 2002-10-18 | 2004-04-22 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| FR2847899B1 (fr) * | 2002-11-29 | 2006-04-28 | Sanofi Synthelabo | Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique |
| BR0316950A (pt) * | 2002-12-02 | 2006-01-17 | Hoffmann La Roche | Derivados de indazol como antagonistas de crf |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| KR100674769B1 (ko) * | 2003-01-02 | 2007-02-28 | 에프. 호프만-라 로슈 아게 | 신규 씨비 1 수용체 역작용제 |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7622471B2 (en) | 2003-02-07 | 2009-11-24 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives having a pyridazine and pyridine functionality |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| SE0300705D0 (sv) * | 2003-03-14 | 2003-03-14 | Biolipox Ab | New compounds |
| TW200505902A (en) * | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| SE0300908D0 (sv) * | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| MXPA05011922A (es) * | 2003-05-07 | 2006-02-17 | Pfizer Prod Inc | Ligandos del receptor de cannabinoides y sus usos. |
| CN1809552A (zh) * | 2003-05-20 | 2006-07-26 | 田纳西大学研究基金会 | 大麻素衍生物、其制备方法和用途 |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| JP4786147B2 (ja) * | 2003-06-26 | 2011-10-05 | 武田薬品工業株式会社 | カンナビノイド受容体調節剤 |
| DE60305025T2 (de) | 2003-07-14 | 2006-10-12 | 3M Espe Ag | Klebstoffzusammensetzung mit verringerter Polarität nach der Polymerisation |
| CA2532965C (en) | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
| AU2004265101B2 (en) * | 2003-08-14 | 2009-06-11 | F. Hoffmann-La Roche Ag | Gabanergic modulators |
| WO2005023761A2 (en) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| TWI336697B (en) * | 2003-09-19 | 2011-02-01 | Solvay Pharm Bv | Thiazole derivatives as cannabinoid receptor modulators |
| ATE547404T1 (de) | 2003-09-22 | 2012-03-15 | Msd Kk | Piperidinderivate |
| US7151097B2 (en) | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| WO2005058327A1 (en) * | 2003-12-17 | 2005-06-30 | Akzo Nobel N.V. | Tricyclic 1-[(3-indol-3-yl)carbonyl] piperazine derivatives as cannabinoid cb1 receptor agonists |
| CN100540005C (zh) * | 2003-12-17 | 2009-09-16 | 欧加农股份有限公司 | 作为大麻素cb1受体激动剂的三环的1-[(3-吲哚-3-基)羰基]哌嗪衍生物 |
| DK1697371T3 (da) | 2003-12-19 | 2007-09-17 | Bristol Myers Squibb Co | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer |
| RU2389729C2 (ru) | 2003-12-22 | 2010-05-20 | Мемори Фармасьютиклз Корпорейшн | 1н-индазолы, 1, 2-бензизоксазолы и 1, 2-бензизотиазолы, их получение и применение |
| TW200522944A (en) * | 2003-12-23 | 2005-07-16 | Lilly Co Eli | CB1 modulator compounds |
| GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
| GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| ES2244314B1 (es) * | 2004-02-17 | 2007-02-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos. |
| RU2375349C2 (ru) * | 2004-02-20 | 2009-12-10 | Астразенека Аб | Производные 3-замещенного 1,5-дифенилпиразола, полезные в качестве св1 модуляторов |
| GB0403864D0 (en) * | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
| TWI330635B (en) * | 2004-03-05 | 2010-09-21 | Organon Nv | (indol-3-yl)-heterocycle derivatives |
| EP1735286B1 (en) * | 2004-03-24 | 2012-01-04 | Janssen Pharmaceutica NV | Tetrahydro-indazole cannabinoid modulators |
| EP1735306A2 (en) | 2004-03-25 | 2006-12-27 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| CA2567977A1 (en) * | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| NZ551712A (en) * | 2004-05-07 | 2010-07-30 | Memory Pharm Corp | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof |
| ES2324720T3 (es) * | 2004-05-10 | 2009-08-13 | F. Hoffmann-La Roche Ag | Pirrol o imidazol amidas para tratar la obesidad. |
| KR20070034049A (ko) | 2004-06-09 | 2007-03-27 | 글락소 그룹 리미티드 | 피롤로피리딘 유도체 |
| KR101764575B1 (ko) * | 2004-07-28 | 2017-08-03 | 다케다 야쿠힌 고교 가부시키가이샤 | 피롤로〔2,3-ｃ〕피리딘 화합물, 그 제조 방법 및 용도 |
| EP1773781A2 (en) | 2004-08-03 | 2007-04-18 | Wyeth | Indazoles useful in treating cardiovascular diseases |
| FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
| FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| WO2006032852A1 (en) * | 2004-09-20 | 2006-03-30 | Biolipox Ab | Pyrazole compounds useful uin the treatment of inflammation |
| WO2006032851A1 (en) | 2004-09-20 | 2006-03-30 | Biolipox Ab | Pyrazole compounds useful in the treatment of inflammation |
| CN101027285A (zh) * | 2004-09-27 | 2007-08-29 | 辉瑞产品公司 | 制备双环吡唑基化合物的方法 |
| EP1807070A1 (en) * | 2004-09-29 | 2007-07-18 | Schering Corporation | Combinations of substituted azetidinones and cb1 antagonists |
| CN101094689B (zh) | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
| SE0402763D0 (sv) * | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Nitro indazole derivatives |
| CN102633730A (zh) | 2004-12-03 | 2012-08-15 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| US7560481B2 (en) * | 2004-12-21 | 2009-07-14 | Abbott Laboratories | Indoles are cannabinoid receptor ligands |
| CA2591817A1 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| JP2008525404A (ja) * | 2004-12-23 | 2008-07-17 | アストラゼネカ アクチボラグ | 治療剤 |
| WO2006076569A2 (en) | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| MX2007008781A (es) | 2005-01-21 | 2007-09-11 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| CN101146532B (zh) | 2005-01-21 | 2012-05-09 | 阿斯泰克斯治疗有限公司 | 药物化合物 |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| CA2601777A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| US8937184B2 (en) | 2005-02-16 | 2015-01-20 | Abbvie B.V. | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators |
| JP2008530179A (ja) * | 2005-02-16 | 2008-08-07 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | カンナビノイドｃｂ２受容体モジュレーターとしての１ｈ−イミダゾール誘導体 |
| TW200700387A (en) | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
| WO2006101434A1 (en) * | 2005-03-22 | 2006-09-28 | Astrazeneca Ab | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| EP1863479B1 (en) * | 2005-03-31 | 2008-12-10 | Janssen Pharmaceutica N.V. | Tetrahydrothiopyrano pyrazole cannabinoid modulators cross reference to related applications |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| BRPI0610580B8 (pt) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | composto derivado de piperidina |
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| CA2613678A1 (en) * | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| GB0514738D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Therapeutic agents |
| GB0516379D0 (en) * | 2005-08-09 | 2005-09-14 | Glaxo Group Ltd | Compounds |
| JPWO2007018248A1 (ja) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | ピリドン化合物 |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| AU2006280511A1 (en) * | 2005-08-12 | 2007-02-22 | Astrazeneca Ab | Process |
| US7763732B2 (en) | 2005-08-24 | 2010-07-27 | N.V. Organon | Indole derivatives |
| WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
| WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
| JP2009508954A (ja) * | 2005-09-23 | 2009-03-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換３−アミド−テトラヒドロ−インダゾリル系カンナビノイドモジュレーター |
| US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB2431105A (en) * | 2005-10-12 | 2007-04-18 | Gw Pharma Ltd | Cannabinoids for the treatment of pulmonary disorders |
| TW200800911A (en) * | 2005-10-20 | 2008-01-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
| EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
| EP1943234A1 (en) * | 2005-10-31 | 2008-07-16 | Biolipox AB | Triazole compounds as lipoxygenase inhibitors |
| TW200732320A (en) * | 2005-10-31 | 2007-09-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
| JP2009513692A (ja) * | 2005-11-01 | 2009-04-02 | バイオリポックス エービー | 炎症の治療に有用なピラゾール化合物 |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| ES2381205T3 (es) | 2005-11-10 | 2012-05-24 | Msd K.K. | Derivado espiro aza-sustituido |
| WO2007079239A2 (en) * | 2005-12-30 | 2007-07-12 | Acadia Pharmaceuticals Inc. | Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof |
| TWI386405B (zh) | 2006-09-05 | 2013-02-21 | 咪唑衍生物 | |
| US8236841B2 (en) | 2006-09-13 | 2012-08-07 | Kyowa Hakko Kirin Co., Ltd. | Fused heterocycle derivative |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| CN101677977A (zh) * | 2006-11-10 | 2010-03-24 | 欣达克斯制药公司 | 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合 |
| CA2673177A1 (en) | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Modulators of cb1 receptors |
| WO2008085302A1 (en) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| TW200848039A (en) * | 2007-02-09 | 2008-12-16 | Astrazeneca Ab | Pharmaceutical compositions |
| TW200848417A (en) | 2007-02-22 | 2008-12-16 | Organon Nv | Indole derivatives |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| US7781650B2 (en) * | 2007-04-30 | 2010-08-24 | Monsanto Technology Llc | Plants and seeds of corn variety CV202909 |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009015180A2 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
| CA2695437A1 (en) * | 2007-08-06 | 2009-02-12 | Yoshihiro Horiuchi | Aminopyrazole amide derivative |
| CA2691512A1 (en) * | 2007-08-10 | 2009-02-19 | H. Lundbeck A/S | Heteroaryl amide analogues |
| EP2203171A2 (en) * | 2007-08-21 | 2010-07-07 | Merck Sharp & Dohme Corp. | Cb2 receptor ligands for the treatment of pain |
| US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| EP2234966B1 (fr) * | 2007-12-18 | 2013-09-11 | Sanofi | Derives d'azetidines, leur preparation et leur application en therapeutique |
| KR101614723B1 (ko) | 2008-01-11 | 2016-04-22 | 알바니 몰레큘라 리써치, 인크. | Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌 |
| US8957063B2 (en) * | 2008-02-21 | 2015-02-17 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the CB2 receptor |
| MX2010009462A (es) * | 2008-02-29 | 2010-09-24 | Pfizer | Derivados de indazol. |
| WO2009106980A2 (en) * | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| EP2264026A4 (en) | 2008-03-06 | 2012-03-28 | Msd Kk | ALKYLAMINOPYRIDINDERIVATE |
| US8815892B2 (en) | 2008-03-25 | 2014-08-26 | Affectis Pharmaceuticals Ag | P2X7R antagonists and their use |
| BRPI0910034B1 (pt) * | 2008-03-25 | 2022-02-08 | Affectis Pharmaceuticals Ag | Antagonistas do p2x7r e composições farmacêuticas que os compreendem |
| WO2009119726A1 (ja) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
| AU2009239430B2 (en) | 2008-04-21 | 2015-01-22 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| JPWO2009154132A1 (ja) | 2008-06-19 | 2011-12-01 | Ｍｓｄ株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| MX2011004551A (es) | 2008-10-30 | 2011-05-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida. |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
| US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| WO2011003007A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| JP2012532144A (ja) | 2009-07-01 | 2012-12-13 | アルバニー モレキュラー リサーチ， インコーポレイテッド | アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用 |
| US8575186B2 (en) * | 2009-10-05 | 2013-11-05 | Albany Molecular Research, Inc. | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
| US8697700B2 (en) | 2010-12-21 | 2014-04-15 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof |
| PT2661433T (pt) * | 2011-01-04 | 2017-10-24 | Novartis Ag | Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd) |
| EP2668191A4 (en) | 2011-01-19 | 2014-08-20 | Albany Molecular Res Inc | BENZOFURO- [3,2-C-] PYRIDINES AND RELATED ANALOGS AS SEROTONIN-SUBTYPE-6 (5-HT6) MODULATORS FOR THE TREATMENT OF ADIPOSITAS, METABOLISM SYNDROME, COGNITION AND SCHIZOPHRENIA |
| US8791132B2 (en) | 2011-02-18 | 2014-07-29 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| WO2012144661A1 (en) | 2011-04-20 | 2012-10-26 | Shionogi & Co., Ltd. | Aromatic heterocyclic derivative having trpv4-inhibiting activity |
| JP2014527511A (ja) | 2011-06-24 | 2014-10-16 | アムジエン・インコーポレーテツド | Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用 |
| EP2723718A1 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| CA2875842A1 (en) * | 2012-05-11 | 2013-11-14 | The University Of Utah Research Foundation | Compounds with trpv4 activity, compositions and associated methods thereof |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| RU2520967C1 (ru) * | 2013-02-08 | 2014-06-27 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | СИММЕТРИЧНЫЕ ДИИМИНЫ НА ОСНОВЕ КАМФОРЫ - ИНГИБИТОРЫ РЕПРОДУКЦИИ ВИРУСА ГРИППА (ШТАММ A/California/07/09 (H1N1)pdm09) |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| EA027935B1 (ru) | 2013-03-07 | 2017-09-29 | Ф. Хоффманн-Ля Рош Аг | Новые производные пиразола |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| HUE035333T2 (en) | 2013-05-02 | 2018-05-02 | Hoffmann La Roche | Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists |
| CN105209466B (zh) | 2013-05-02 | 2018-05-18 | 豪夫迈·罗氏有限公司 | 作为cb2受体激动剂的嘌呤衍生物 |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| PL3041843T3 (pl) | 2013-09-06 | 2019-06-28 | F. Hoffmann-La Roche Ag | Pochodne triazolo[4,5-d]pirymidyny jako antagoniści receptora cb2 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| AU2014353894A1 (en) * | 2013-11-25 | 2016-06-02 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents |
| KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| AR105911A1 (es) | 2015-09-03 | 2017-11-22 | Forma Therapeutics Inc | Inhibidores de hdac8 bicíclicos fusionados [6,6] |
| AU2016320645B2 (en) | 2015-09-10 | 2019-02-28 | Suven Life Sciences Limited | Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators |
| CA3010615C (en) | 2016-01-14 | 2024-02-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| CN113332292A (zh) | 2016-02-23 | 2021-09-03 | 辉瑞公司 | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 |
| WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| CN108794379A (zh) * | 2017-04-26 | 2018-11-13 | 华东师范大学 | 1h-吲哚-2-甲酰胺衍生物及其制备方法和应用 |
| BR112020000771A2 (pt) * | 2017-07-14 | 2020-07-14 | F. Hoffmann-La Roche Ag | compostos de cetona bicíclica e métodos de uso dos mesmos |
| AR113811A1 (es) | 2017-10-31 | 2020-06-10 | Hoffmann La Roche | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos |
| FI3851436T3 (fi) | 2018-09-10 | 2024-09-03 | Kaken Pharma Co Ltd | Uusi heteroaromaattinen amidijohdannainen ja sitä sisältävä lääke |
| CN109020860B (zh) * | 2018-09-25 | 2021-06-22 | 宝鸡文理学院 | 一种2-芳基-3-酯基多取代吡咯类化合物及其合成精制方法 |
| AR117122A1 (es) | 2018-11-20 | 2021-07-14 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
| CN113302193A (zh) | 2019-01-11 | 2021-08-24 | 豪夫迈·罗氏有限公司 | 双环吡咯并三唑酮化合物及其使用方法 |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| TR202002933A2 (tr) * | 2020-02-26 | 2021-09-21 | Bahcesehir Ueniversitesi | Nörodejenerati̇f hastaliklarin tedavi̇si̇nde kullanilmak üzere yeni̇ mao-b i̇nhi̇bi̇törü drg-maob-1 |
| US20230067205A1 (en) * | 2020-07-29 | 2023-03-02 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
| BR112023002957A2 (pt) | 2020-08-18 | 2023-04-04 | Merck Sharp & Dohme Llc | Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero |
| WO2024052685A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy |
| WO2026020111A1 (en) * | 2024-07-18 | 2026-01-22 | Washington University | Compositions of novel cannabinoid receptor modulators and methods of use thereof |
| CN119330867B (zh) * | 2024-09-03 | 2025-12-02 | 常州大学 | 一种吡咯酰胺类衍生物及其制备方法和作为β2-肾上腺素受体别构拮抗剂的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5632549A (en) | 1979-08-27 | 1981-04-02 | Toyo Ink Mfg Co Ltd | Pigment composition |
| US4581354A (en) | 1984-08-06 | 1986-04-08 | Sterling Drug Inc. | 3-arylcarbonyl- and 3-cycloalkylcarbonyl-1-aminoalkyl-1H-indoles, compositions and use |
| US5013732A (en) | 1984-08-06 | 1991-05-07 | Sterling Drug Inc. | 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles |
| US4748247A (en) * | 1986-10-21 | 1988-05-31 | American Home Products Corporation | 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists |
| EP0306323B1 (en) * | 1987-09-03 | 1994-09-21 | Glaxo Group Limited | Lactam derivatives |
| KR970005300B1 (ko) * | 1987-09-03 | 1997-04-15 | 글락소 그룹 리미티드 | 락탐 유도체 |
| DE68926553T2 (de) * | 1988-08-02 | 1996-10-17 | Glaxo Group Ltd., London | Lactamderivate |
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| FI97540C (fi) * | 1989-11-06 | 1997-01-10 | Sanofi Sa | Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi |
| JPH03161470A (ja) * | 1989-11-17 | 1991-07-11 | Nisshin Flour Milling Co Ltd | インドール誘導体 |
| PT95899A (pt) | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
| IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| CA2036307C (en) | 1990-03-08 | 2002-07-09 | Susan Jean Ward | 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method |
| US5102889B1 (en) * | 1990-09-27 | 1993-05-11 | 2-(4-piperidinyl)-1h-pyrido(4,3-b)indol-1-ones and related compounds | |
| US5189041A (en) * | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
| US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| ES2150941T3 (es) | 1992-04-03 | 2000-12-16 | Upjohn Co | Aminas biciclicas-heterociclicas eficaces farmaceuticamente. |
| FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| WO1994020126A1 (en) * | 1993-03-03 | 1994-09-15 | Fujisawa Pharmaceutical Co., Ltd. | Use of peptides for the manufacture of a medicament |
| WO1994022821A1 (en) * | 1993-04-05 | 1994-10-13 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives as testosterone 5 alpha-reductase inhibitors |
| US5681954A (en) | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
| WO1995000536A1 (en) * | 1993-06-22 | 1995-01-05 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds |
| NZ281431A (en) * | 1994-02-22 | 1997-09-22 | Merrell Pharma Inc | Alkylamide-substituted indole derivatives |
| WO1995026953A1 (en) * | 1994-03-30 | 1995-10-12 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compound and use thereof as medicine |
| GB9420521D0 (en) * | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
| EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
| US5532237A (en) * | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| US5567711A (en) | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
| FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| IL120724A0 (en) | 1995-09-01 | 1997-08-14 | Lilly Co Eli | Indolyl neuropeptide Y receptor antagonists |
| WO1997029079A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| FR2745003B1 (fr) * | 1996-02-16 | 1998-04-03 | Adir | Nouveaux pseudopeptides derives de neurokinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE69822449T2 (de) * | 1997-01-21 | 2005-01-27 | Smithkline Beecham Corp. | Neue cannabinoidrezeptor-modulatoren |
| US5948777A (en) | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
| SK6572000A3 (en) * | 1997-11-05 | 2000-10-09 | Novartis Ag | Dipeptide nitriles, process for the preparation thereof, their use as medicaments and pharmaceutical composition comprising them |
| SK285729B6 (sk) * | 1997-11-18 | 2007-07-06 | Teijin Pharma Limited | Zlúčenina derivátov cyklických amínov a jej použitie |
| JP2002515891A (ja) * | 1997-12-19 | 2002-05-28 | スミスクライン・ビーチャム・コーポレイション | 新規なピペリジン含有化合物 |
| MXPA01002173A (es) * | 1998-08-28 | 2003-07-14 | Scios Inc | Inhibidores de p38-alfa cinasa. |
-
2001
- 2001-02-08 WO PCT/US2001/004131 patent/WO2001058869A2/en not_active Ceased
- 2001-02-08 EP EP01907144A patent/EP1254115A2/en not_active Withdrawn
- 2001-02-08 AU AU2001234958A patent/AU2001234958A1/en not_active Abandoned
- 2001-02-08 CA CA002399791A patent/CA2399791A1/en not_active Abandoned
- 2001-02-08 US US09/779,109 patent/US6653304B2/en not_active Expired - Lifetime
- 2001-02-08 JP JP2001558420A patent/JP2004502642A/ja active Pending
- 2001-02-09 AR ARP010100611A patent/AR027406A1/es unknown
- 2001-02-09 PE PE2001000145A patent/PE20020746A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004502642A5 (https=) | ||
| CN101611013B (zh) | 作为5-ht2a血清素受体调节剂用于治疗与其相关病症的吡唑衍生物 | |
| AU2007254244B2 (en) | 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | |
| EP2018371B1 (en) | Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| US6653304B2 (en) | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases | |
| HRP20170338T1 (hr) | Fluorometil-supstituirani pirolkarboksamidi | |
| ES2314750T3 (es) | Derivados de 3-fenil-pirazol como moduladores del receptor 5ht-2a de la serotonina utiles para el tratamiento de trastornos relacionados con el mismo. | |
| FI104069B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 3-(fenyyli- tai sykloalkyyli)-3-hydroksi-1-fenyylisulfonyyli-2-indoliinikarboksamidijohdannaisten valmistamiseksi | |
| US8293770B2 (en) | Pyrrolidine derivatives as NK-3 receptor antagonists | |
| JP2013516415A5 (https=) | ||
| ES2324710T3 (es) | Indolinonas sustituidas con heterociclos y su uso como inhibidores de receptores de tirosina quinasa. | |
| JP2009541461A5 (https=) | ||
| JP2014521595A5 (https=) | ||
| JP2012502975A5 (https=) | ||
| JP2005535655A (ja) | ムスカリン性受容体拮抗剤としてのアザビシクロ誘導体 | |
| WO2014133056A1 (ja) | ２－アシルアミノチアゾール誘導体またはその塩 | |
| JP2009525312A (ja) | スルホンアミド誘導体、これの調製および治療への応用 | |
| JP2006525299A5 (https=) | ||
| CA2329881A1 (en) | Compounds with growth hormone releasing properties | |
| CN118574807A (zh) | 抑制单酰基甘油脂肪酶（magl） | |
| KR101304802B1 (ko) | 3-(벤질아미노)-피롤리딘 유도체 및 이의 ｎｋ-3 수용체 길항제로서의 용도 | |
| US5565579A (en) | (1H-indol-1-yl)-2-(amino)acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides | |
| JP6199902B2 (ja) | イミダゾリルケトン誘導体ａｓｄアルドステロン合成酵素阻害剤 | |
| JP5243274B2 (ja) | ４型メラノコルチン受容体アゴニストのピペリジノイルピロリジン | |
| HRP20140607T1 (hr) | Predlijekovi [4[4-(5-aminometil-2-fluorfenil)piperidin-1-il](1h-pirolopiridinil)metanona i njihova sinteza |